Pages that link to "Item:Q5295377"
From MaRDI portal
The following pages link to Augmented Designs to Assess Immune Response in Vaccine Trials (Q5295377):
Displaying 25 items.
- Design and analysis of vaccine studies (Q1040907) (← links)
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy (Q2001894) (← links)
- Identification of causal effects within principal strata using auxiliary variables (Q2075703) (← links)
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
- Vaccinations in disease models with antibody-dependent enhancement (Q2476100) (← links)
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model (Q2482986) (← links)
- Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
- Surrogate measures and consistent surrogates (Q2861938) (← links)
- Comparing biomarkers as principal surrogate endpoints (Q2893405) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- Augmented Designs to Assess Principal Strata Direct Effects (Q3107200) (← links)
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling (Q3119801) (← links)
- Incorporating founder virus information in vaccine field trials (Q3459936) (← links)
- Evaluating Candidate Principal Surrogate Endpoints (Q3549407) (← links)
- A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint (Q4649074) (← links)
- A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework (Q4984852) (← links)
- Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments (Q5850972) (← links)
- A unified evaluation of differential vaccine efficacy (Q6047741) (← links)
- Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy (Q6055756) (← links)
- Assurance in vaccine efficacy clinical trial design based on immunological responses (Q6085899) (← links)
- Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials (Q6626858) (← links)
- Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm (Q6628202) (← links)
- Assessing vaccine durability in randomized trials following placebo crossover (Q6628297) (← links)
- Translating questions to estimands in randomized clinical trials with intercurrent events (Q6628626) (← links)
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials (Q6636037) (← links)
